Infertility drugs help improve egg health, support ovulation, and enhance the chances of conception. These drugs improve egg and sperm production and function. In vitro fertilization procedures are also associated with the infertility drugs market.
The global Infertility Drugs Market is estimated to be valued at US$3699.8 Million in 2024 and is expected to exhibit a CAGR Of 5.9% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends driving the growth of the infertility drugs market is the rising number of cases related to infertility across various regions. Factors such as increasing stress levels, changing lifestyle, rising pollution levels, and growing prevalence of diseases like Polycystic Ovarian Syndrome (PCOS) are contributing significantly to the rising incidence of infertility globally. According to the Centers for Disease Control and Prevention (CDC), around 12% of women aged 15-44 years in the U.S. have difficulty getting pregnant or carrying a pregnancy to term, regardless of marital status. This rising infertility rate has resulted in increasing demand for infertility treatment drugs. This trend is expected to continue over the forecast period and significantly support the overall expansion of the global infertility drugs market.
Segment Analysis
The global infertility drugs market is segmented based on drug type, treatment type, distribution channel and region. Based on drug type, the market is segmented into clomiphene citrate, letrozole, tamoxifen citrate and others. Clomiphene citrate dominates the market and holds around 50% market share owing to its increased usage for ovulation induction as the first line treatment. Based on treatment type, the market is segmented into ovulation stimulation, female infertility treatment, and male infertility treatment. The female infertility treatment segment dominates the market owing to increasing cases of PCOS and other reproductive issues in women.
Key Takeaways
The Global Infertility Drugs Market Demand is expected to witness high growth over the forecast period owing to rising cases of infertility worldwide. The global infertility drugs market is estimated to be valued at US$3699.8 million in 2024 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030.
Regional analysis
North America is expected to continue dominating the global infertility drugs market during the forecast period. This is attributed to growing awareness regarding infertility diagnosis and treatment, higher healthcare expenditure and presence of well-established healthcare facilities in the region. Asia Pacific market is projected to witness the highest CAGR during the forecast period owing to improving healthcare infrastructure, rising fertility tourism industry and increasing public & private funding for infertility treatment in countries such as India and China.
Key players
Key players operating in the infertility drugs market include Merck & Co., Ferring Pharmaceuticals, LIVZON Pharmaceutical Group Inc., Instituto Inotech S.A., Abbott Laboratories, Biogen, Bayer HealthCare and EMD Serono. Merck & Co. dominates the global infertility drugs market with its two pivotal brands - clomiphene citrate (Clomid) and letrozole (Femara). Instituto Inotech S.A. offers innovative fertility medications for ovulation induction, fertility preservation and intrauterine insemination treatments.
Get more insights on this topic :
Check more trending articles on this topic:
https://filmik.in/cell-therapy-harmonizing-hope-through-the-therapeutic-rhythm-of-cellular-alchemy/
